Supreme Court Lets $194 Million Eli Lilly Medicaid Fraud Award Stand

1 articles · Updated · Bloomberg · May 18

$194 million in damages against Eli Lilly remained intact after the US Supreme Court declined to hear the drugmaker's appeal in a whistleblower Medicaid fraud case.
Eli Lilly had sought not only to overturn the award but also to strike down the False Claims Act's qui tam mechanism, arguing it unconstitutionally lets private parties enforce federal law and share recoveries.
The justices gave no comment, leaving in place a ruling tied to allegations that Lilly misreported drug prices to Medicaid.
The decision preserves a key enforcement tool the federal government and whistleblowers use to pursue fraud claims against companies doing business with public programs.

With conflicting court rulings on drug pricing, how can pharmaceutical firms now avoid massive 'unwary trap' fraud penalties?

As AI now polices Medicaid, are whistleblower lawsuits becoming obsolete or even more powerful tools against corporate fraud?

After Lilly’s $194M penalty, will pharma giants challenge the new GENEROUS model tying US drug prices to international rates?